Hikari Okada

1.7k total citations
49 papers, 1.1k citations indexed

About

Hikari Okada is a scholar working on Molecular Biology, Epidemiology and Hepatology. According to data from OpenAlex, Hikari Okada has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Epidemiology and 20 papers in Hepatology. Recurrent topics in Hikari Okada's work include Liver Disease Diagnosis and Treatment (13 papers), Hepatitis B Virus Studies (10 papers) and Hepatitis C virus research (9 papers). Hikari Okada is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Hepatitis B Virus Studies (10 papers) and Hepatitis C virus research (9 papers). Hikari Okada collaborates with scholars based in Japan, United States and Italy. Hikari Okada's co-authors include Masao Honda, Taro Yamashita, Yoshio Sakai, Takayoshi Shirasaki, Tetsuro Shimakami, Shuichi Kaneko, Shuichi Kaneko, Eishiro Mizukoshi, Kouki Nio and Kuniaki Arai and has published in prestigious journals such as Journal of Biological Chemistry, Hepatology and Cancer Research.

In The Last Decade

Hikari Okada

46 papers receiving 1.1k citations

Peers

Hikari Okada

EPIDE

HEPAT

ONCOL

Hui‐Lu Zhang China

Pan Zhao China

Ryosuke Muroyama Japan

Myoung-Kuk Jang South Korea

Jens‐Gerd Scharf Germany

Wannan Chen China

Hyuk Soo Eun South Korea

Suxian Zhao China

Komal Ramani United States

Elena Kotsiliti United Kingdom

Hui‐Lu Zhang China

Hikari Okada

571 ×1.0

290 ×0.8

EPIDE

221 ×0.6

HEPAT

308 ×1.0

276 ×1.6

ONCOL

Citations per year, relative to Hikari Okada Hikari Okada (= 1×) peers Hui‐Lu Zhang

Countries citing papers authored by Hikari Okada

Since Specialization

Citations

This map shows the geographic impact of Hikari Okada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hikari Okada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hikari Okada more than expected).

Fields of papers citing papers by Hikari Okada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hikari Okada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hikari Okada. The network helps show where Hikari Okada may publish in the future.

Co-authorship network of co-authors of Hikari Okada

This figure shows the co-authorship network connecting the top 25 collaborators of Hikari Okada. A scholar is included among the top collaborators of Hikari Okada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hikari Okada. Hikari Okada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okada, Hikari, Alessandro Nasti, Yoshio Sakai, et al.. (2025). Evaluation of Long-Read RNA Sequencing Procedures for Novel Isoform Identification and Quantification in Human Whole Blood. Genes. 16(9). 1075–1075.

Mizukoshi, Eishiro, Shihui Li, Takuya Seike, et al.. (2025). Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease. Journal of Gastroenterology. 60(8). 990–999. 1 indexed citations

Funahashi, Nobuaki, Hikari Okada, Ryo Kaneko, et al.. (2024). Hepatocyte transformation is induced by laminin γ2 monomer. Cancer Science. 115(9). 2972–2984. 2 indexed citations

Nio, Kouki, Tetsuro Shimakami, Kazuyuki Kuroki, et al.. (2023). Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors. Viruses. 15(5). 1178–1178. 5 indexed citations

Tanaka, Noritaka, Hikari Okada, Kiyoshi Yamaguchi, et al.. (2023). Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation. Cell Death and Disease. 14(12). 815–815. 5 indexed citations

Li, Ru, Hikari Okada, Taro Yamashita, et al.. (2022). FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. International Journal of Molecular Sciences. 23(15). 8305–8305. 10 indexed citations

Yamashita, Taro, Hajime Sunagozaka, Hikari Okada, et al.. (2022). Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. International Journal of Molecular Sciences. 23(5). 2801–2801. 23 indexed citations

Iida, Noriho, Eishiro Mizukoshi, Tatsuya Yamashita, et al.. (2021). Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nature Cancer. 2(10). 1039–1054. 55 indexed citations

Shirasaki, Takayoshi, Masao Honda, Hikari Okada, et al.. (2021). Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. Scientific Reports. 11(1). 13021–13021. 2 indexed citations

10.

Seike, Takuya, Eishiro Mizukoshi, Kazutoshi Yamada, et al.. (2020). Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. Journal of Gastroenterology. 55(7). 701–711. 18 indexed citations

11.

Shirasaki, Takayoshi, Masao Honda, Tetsuro Shimakami, et al.. (2018). Peretinoin, an Acyclic Retinoid, Inhibits Hepatitis B Virus Replication by Suppressing Sphingosine Metabolic Pathway In Vitro. International Journal of Molecular Sciences. 19(2). 108–108. 7 indexed citations

12.

Shirasaki, Takayoshi, Masao Honda, Taro Yamashita, et al.. (2018). The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Scientific Reports. 8(1). 13143–13143. 27 indexed citations

13.

Hayashi, Tomoyuki, Taro Yamashita, Hikari Okada, et al.. (2017). A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma. Anticancer Research. 37(7). 3397–3403. 13 indexed citations

14.

Hayashi, Tomoyuki, Taro Yamashita, Takeshi Terashima, et al.. (2017). Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer. 17(1). 870–870. 26 indexed citations

15.

Nomura, Yoshimoto, Taro Yamashita, Naoki Oishi, et al.. (2017). De Novo Emergence of Mesenchymal Stem-Like CD105+ Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma. Translational Oncology. 10(2). 184–189. 16 indexed citations

16.

Shimakami, Tetsuro, Naoto Nagata, Hikari Okada, et al.. (2017). Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Scientific Reports. 7(1). 16978–16978. 29 indexed citations

17.

Kawaguchi, Kazunori, Masao Honda, Taro Yamashita, et al.. (2016). Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer. American Journal Of Pathology. 186(8). 2055–2067. 20 indexed citations

18.

Honda, Masao, Takayoshi Shirasaki, Takeshi Terashima, et al.. (2015). Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. The Journal of Infectious Diseases. 213(7). 1096–1106. 84 indexed citations

19.

Okada, Hikari, Masao Honda, Jean S. Campbell, et al.. (2012). Acyclic Retinoid Targets Platelet-Derived Growth Factor Signaling in the Prevention of Hepatic Fibrosis and Hepatocellular Carcinoma Development. Cancer Research. 72(17). 4459–4471. 48 indexed citations

20.

Shirasaki, Takayoshi, Masao Honda, Kazunori Kawaguchi, et al.. (2010). HCV-INFECTION-SPECIFIC MIRNAS CAPABLE OF REGULATING HCV REPLICATION. Hepatology. 52(4). 821–822. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact